ClinicalTrials.Veeva

Menu

Assessment of Urinary NGAL to Predict AKI in Children Receiving Multiple Nephrotoxic Medications (NINJA NGAL)

Cincinnati Children's Hospital Medical Center logo

Cincinnati Children's Hospital Medical Center

Status

Completed

Conditions

Acute Kidney Injury
Nephrotoxicity

Study type

Observational

Funder types

Other
Industry

Identifiers

NCT03527160
CIN001 - NINJA NGAL

Details and patient eligibility

About

Nephrotoxic medication (NTMx) exposure is one of the most commonly cited causes of acute kidney injury (AKI) in hospitalized children, and is the primary cause of AKI in 16% of cases. Through initial work at Cincinnati Children's Medical Center, NTMx exposure was found to be potentially modifiable and the associated AKI is an avoidable adverse safety event. Currently, only serum Creatinine monitoring is available to monitor for NTMx-associated AKI. The hypotheses of this NINJA NGAL study are that (1) urine NGAL is highly sensitive to detect NTMx-associated AKI, and (2) Bedside test of urine from high risk NTMx-exposed patients are adequate and reliable compared to urine NGAL measured from the clinical platform.

Enrollment

134 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Receiving 3 or more nephrotoxic medications on the same day OR
  • Receiving 3 or more days of an intravenous aminoglycoside or vancomycin

Exclusion criteria

  • Currently being treated for a urinary tract infection
  • Presence of an acute kidney injury prior to enrollment

Trial design

Trial documents
1

Trial contacts and locations

2

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems